Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_1
3
43%
Ph phase_2
3
43%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Terminated(4)
Other(3)

Detailed Status

Withdrawn3
Suspended2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

unknown114%
withdrawn343%
suspended229%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

NCT00310128
withdrawnphase_2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

NCT00253526
withdrawnphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403
suspendedphase_3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831
terminatedphase_2

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT00265928
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00310128Phase 2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Withdrawn
NCT00253526Phase 2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn
NCT00052403Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Withdrawn
NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended
NCT00265928Phase 2

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated
NCT00077493Phase 1

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Suspended
NCT00515892Phase 1

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Unknown

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7